MindBio Therapeutics Corp. announced a significant breakthrough based on sleep data collected during randomized controlled trials of LSD-Microdosing. The trials involved 80 participants, and a total of 3,231 nights of sleep data were analyzed.

A Media Snippet accompanying this announcement is available by clicking on the image or link below: MindBio Therapeutics streaming video For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. Based on initial findings from the sleep data collected during the trials, which included the recording, measurement, and analysis of sleep patterns in both the LSD-Microdosing treatment group of 40 participants and the placebo group of 40 participants, the company confirmed positive sleep responses to its LSD-Microdosing treatment. The advantage of microdosing LSD as opposed to macrodosing is that patients can take the drug and then get on with their day in much the same way they would when taking anti-depressant medication.

Notably, LSD-Microdosing not only improves subjective feelings related to mood, happiness, energy, creativity, social connectivity, and wellness, but it also has a statistically significant impact on sleep quality. As many as 1 in 5 adults in the USA struggle to fall asleep every single night, with half of US adults experiencing insomnia once a month or more.